The pharmaceutical industry quest to throw out Medicare’s drug price negotiation authority is unlikely to gain much new ammunition thanks to a handful of recent anti-regulatory decisions from the US Supreme Court, most notably the elimination of the Chevron doctrine of judicial deference to an agency’s interpretation of a statute that is ambiguous.
Key Takeaways
-
The Inflation Reduction Act was written in a way that experts believe should insulate it somewhat from recent anti-regulatory decisions from the US Supreme Court.
But drug manufacturers could use the recent Chevron overhaul to score some smaller victories in how the negotiation program, set...








